{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:28:13Z","timestamp":1792740493096,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":3739,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.fertnstert.2011.12.046","type":"journal-article","created":{"date-parts":[[2012,1,28]],"date-time":"2012-01-28T09:25:51Z","timestamp":1327742751000},"page":"517-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Etiology of OHSS and use of dopamine agonists"],"prefix":"10.1016","volume":"97","author":[{"given":"S\u00e9rgio Reis","family":"Soares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2011.12.046_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1196\/annals.1365.021","article-title":"Prevention and management of ovarian hyperstimulation syndrome","volume":"1092","author":"Vlahos","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib2","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.fertnstert.2009.07.1662","article-title":"The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome","volume":"94","author":"Grossman","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib3","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade","volume":"143","author":"G\u00f3mez","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/humupd\/3.3.255","article-title":"The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome","volume":"3","author":"Rizk","year":"1997","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib5","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1095\/biolreprod.102.010801","article-title":"Administration of moderate and high doses of gonadotrophins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability","volume":"68","author":"G\u00f3mez","year":"2003","journal-title":"Biol Reprod"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib6","first-page":"157","article-title":"Expression of vascular permeability factor\/vascular endothelial growth factor by human granulose and theca lutein cells. Role in corpus luteum development","volume":"146","author":"Kamat","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib7","first-page":"421a","article-title":"Hypoxia stimulates expression of the gene for vascular endothelial growth factor (VEGF), a putative angiogenic factor, by granulosa cells of the ovarian follicle, a site of angiogenesis","volume":"115","author":"Koos","year":"1991","journal-title":"J Cell Biol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib8","first-page":"1723","article-title":"Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in\u00a0vitro","volume":"77","author":"Yan","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib9","first-page":"1967","article-title":"Human chorionic gonadotrophin-dependent expression of vascular endothelial growth factor\/VP factor in human granulosa cells: importance in ovarian hyperstimulation syndrome","volume":"80","author":"Neulen","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/09513599709152564","article-title":"Expression of vascular endothelial growth factor (VEGF) during folliculogenesis and corpus luteum formation in the human ovary","volume":"11","author":"Yamamoto","year":"1997","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0015-0282(98)00484-1","article-title":"The pathogenesis of ovarian hyperstimulation syndrome: in\u00a0vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor","volume":"71","author":"Pellicer","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib12","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1210\/jcem.87.7.8651","article-title":"Human chorionic gonadotrophin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor","volume":"87","author":"Wang","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/molehr\/8.5.409","article-title":"The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome","volume":"8","author":"Albert","year":"2002","journal-title":"Mol Hum Reprod"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib15","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/endo-127-2-965","article-title":"Vascular endothelial growth factor is expressed in rat corpus luteum","volume":"127","author":"Phillips","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib17","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","article-title":"Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor","volume":"269","author":"Waltenberger","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib18","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1074\/jbc.M002016200","article-title":"Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants","volume":"276","author":"Gille","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1537-1891(03)00011-9","article-title":"Regulation of vascular permeability by vascular endothelial growth factors","volume":"39","author":"Bates","year":"2002","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1046\/j.1469-7580.2002.00066.x","article-title":"Regulation of microvascular permeability by vascular endothelial growth factors","volume":"200","author":"Bates","year":"2002","journal-title":"J Anat"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib21","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1074\/jbc.270.12.6729","article-title":"Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediator of signal transduction that contains SH2 domains. Association with endothelial cell proliferation","volume":"270","author":"Guo","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(94)93001-5","article-title":"Vascular endothelial cell growth factor as permeability agent in ovarian hyperstimulation syndrome","volume":"344","author":"McClure","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib23","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1172\/JCI4814","article-title":"Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome","volume":"102","author":"Levin","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0015-0282(97)81908-5","article-title":"Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome","volume":"67","author":"Abramov","year":"1997","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0015-0282(98)00447-6","article-title":"Serum vascular endothelial growth factor concentrations in in\u00a0vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome","volume":"71","author":"Agrawal","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0015-0282(99)00206-X","article-title":"Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome","volume":"72","author":"Chen","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib27","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1517\/14712598.3.2.263","article-title":"VEGF blocking therapy in the treatment of cancer","volume":"3","author":"Glade-Bender","year":"2003","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib29","first-page":"3377","article-title":"Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap (A40)","volume":"86","author":"Wulff","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/mvre.2001.2312","article-title":"Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea","volume":"62","author":"Zimmermann","year":"2001","journal-title":"Microvasc Res"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib31","first-page":"768","article-title":"Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey","volume":"86","author":"Zimmermann","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib32","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI200318740","article-title":"Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotrophin-dependent follicle development","volume":"112","author":"Zimmermann","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib33","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1095\/biolreprod.102.006700","article-title":"Inhibition of vascular endothelial growth factor\/vascular permeability factor action blocks estrogen-induced uterine edema and implantation in rodents","volume":"67","author":"Rockwell","year":"2002","journal-title":"Biol Reprod"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1530\/rep.0.1250337","article-title":"Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse","volume":"125","author":"Heryanto","year":"2003","journal-title":"Reproduction"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib35","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/en.2004-0765","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent","volume":"146","author":"Pauli","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib36","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/oxfordjournals.humrep.a137613","article-title":"Dopamine treatment for severe ovarian hyperstimulation syndrome","volume":"7","author":"Ferraretti","year":"1992","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib37","first-page":"281","article-title":"Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine","volume":"17","author":"Tsunoda","year":"2003","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib38","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/humrep\/16.11.2263","article-title":"Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome","volume":"16","author":"Papaleo","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000180041","article-title":"Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma","volume":"21","author":"Eljarmak","year":"1985","journal-title":"Horm Res"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib40","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1023\/A:1018862309440","article-title":"Alteration of dopamine D2 receptors in human malignant stomach tissue","volume":"42","author":"Basu","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib41","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1158\/0008-5472.CAN-04-1600","article-title":"Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor\/vascular endothelial growth factor-mediated angiogenesis","volume":"64","author":"Basu","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/87895","article-title":"The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor\/vascular endothelial growth factor","volume":"7","author":"Basu","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejogrb.2005.01.009","article-title":"Cabergoline: a safe, easy, cheap, and effective drug for prevention\/treatment of ovarian hyperstimulation syndrome?","volume":"122","author":"Manno","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib44","series-title":"Ovarian hyperstimulation syndrome","author":"Gerris","year":"2006"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1152\/ajplegacy.1954.180.1.47","article-title":"Disturbance of hormone balance in the female rat by a single injection of ergotoxine ethanesulphonate","volume":"180","author":"Shelesnyak","year":"1955","journal-title":"Am J Physiol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib46","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000122476","article-title":"Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats","volume":"20","author":"Mueller","year":"1976","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib47","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/jcem-47-2-290","article-title":"Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors","volume":"47","author":"Mornex","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1210\/jcem-48-1-9","article-title":"A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments","volume":"48","author":"Bigazzi","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0890-6238(96)00063-9","article-title":"Pregnancy outcome after treatment with the ergot derivative, cabergoline","volume":"10","author":"Robert","year":"1996","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF03348017","article-title":"Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy","volume":"20","author":"Ciccarelli","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1015319007880","article-title":"Successful treatment of a large macroprolactinoma with cabergoline during pregnancy","volume":"4","author":"Liu","year":"2001","journal-title":"Pituitary"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib52","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1210\/en.2006-0657","article-title":"Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model","volume":"147","author":"G\u00f3mez","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib53","doi-asserted-by":"crossref","first-page":"16788","DOI":"10.1021\/bi981291f","article-title":"Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR-2 TK), a key enzyme in angiogenesis","volume":"37","author":"Parast","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib54","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1210\/en.2004-1445","article-title":"Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice","volume":"146","author":"Cristina","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib55","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1210\/jc.2011-0075","article-title":"Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment","volume":"96","author":"G\u00f3mez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib56","first-page":"157","article-title":"Expression of vascular permeability factor\/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development","volume":"146","author":"Kamat","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib57","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/humrep\/dep008","article-title":"Superficial ovarian cortex vascularization is inversely related to the follicle reserve in normal cycling ovaries and is increased in polycystic ovary syndrome","volume":"24","author":"Delgado-Rosas","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib58","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.2007-0409","article-title":"Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction","volume":"92","author":"\u00c1lvarez","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0015-0282(16)46753-1","article-title":"Prolactin in the evaluation of luteal phase in infertility","volume":"39","author":"Vanrell","year":"1983","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib60","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1093\/humrep\/dem315","article-title":"Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome (OHSS) in women undergoing ART: a pilot study","volume":"22","author":"\u00c1lvarez","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib61","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0890-6238(02)00055-2","article-title":"Pregnancy outcome after cabergoline treatment in early weeks of gestation","volume":"16","author":"Ricci","year":"2002","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib62","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","article-title":"Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study","volume":"17","author":"Carizza","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib63","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/humupd\/dmq006","article-title":"Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis","volume":"16","author":"Youssef","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib64","unstructured":"Salah Edeen AMR, Alhelou YM. Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone. Abstracts of the 25th Annual Meeting of ESHRE, Amsterdam, the Netherlands, 28 June\u20131 July\u00a02009."},{"key":"10.1016\/j.fertnstert.2011.12.046_bib65","unstructured":"Shaltout A, Shohayeb A, Eid M, Abbas S. Role of cabergoline in preventing ovarian hyperstimulation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome. Abstracts of the 25th Annual Meeting of ESHRE, Amsterdam, the Netherlands, 28 June\u20131 July\u00a02009."},{"key":"10.1016\/j.fertnstert.2011.12.046_bib66","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S1474-4422(07)70218-1","article-title":"Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson\u2019s disease","volume":"6","author":"Antonini","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib67","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib68","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/bmj.b381","article-title":"Dopamine agonists and hyperprolactinaemia","volume":"338","author":"Martin","year":"2009","journal-title":"Br Med J"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib69","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib71","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/humrep\/deq005","article-title":"The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial","volume":"25","author":"Busso","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib72","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0974-1208.69342","article-title":"Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction","volume":"3","author":"Sherwal","year":"2010","journal-title":"J Hum Reprod Sci"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib73","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.fertnstert.2011.02.032","article-title":"Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome","volume":"95","author":"Spitzer","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib74","doi-asserted-by":"crossref","first-page":"1168.e1","DOI":"10.1016\/j.fertnstert.2009.05.021","article-title":"High dose cabergoline in management of ovarian hyperstimulation syndrome","volume":"92","author":"Ata","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2011.12.046_bib75","doi-asserted-by":"crossref","first-page":"1169.e15","DOI":"10.1016\/j.fertnstert.2009.05.062","article-title":"Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and a gonadotropin releasing-hormone antagonist: a case series","volume":"92","author":"Rollene","year":"2009","journal-title":"Fertil Steril"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001502821102930X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001502821102930X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T07:57:04Z","timestamp":1758009424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001502821102930X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S001502821102930X"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2011.12.046","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etiology of OHSS and use of dopamine agonists","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2011.12.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}